Natalie Callander, MD
University of Wisconsin
Interview Date: September 30, 2019
Cancer cells have a different thickness of cell membrane than normal cells. A new treatment is exploiting that difference by delivering a targeted therapy to just the cancer cells while avoiding the normal cells. Cellectar is developing a new treatment called CLR 131, which is a compound that allows the delivery of a radioactive iodine to enter specifically into tumor cells. Radioactive iodine has been used for many years to treat thyroid cancer and has a long history of safety and a short half-life. Dr. Callander describes how this is being used in multiple myeloma and other blood cancers to treat relapsed disease.
Thanks to our episode sponsor
Natalie Callander, MD joined the section of Hematology/Bone Marrow Transplant at the University of Wisconsin in October 2004 as an Associate Professor in the Department of Medicine. Dr. Callander graduated from Tufts University School of Medicine in Boston, MA, has completed residency at Bellevue Hospital in New York, as well as a Hematology/Oncology fellowship at the University of California-San Diego. Her board certifications include hematology, internal medicine, and medical oncology.
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113